Chalkis Health Industry Co., Ltd (SHE:000972)
China
· Delayed Price · Currency is CNY 3.080
-0.030 (-0.96%)
Apr 28, 2025, 2:45 PM CST
Chalkis Health Industry Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Operating Revenue | 294.23 | 559.76 | 576.99 | 165.75 | 0.09 | Upgrade
|
| Other Revenue | 13.92 | 16.02 | 12.3 | 8.7 | 22.88 | Upgrade
|
| Revenue | 308.15 | 575.78 | 589.29 | 174.45 | 22.97 | Upgrade
|
| Revenue Growth (YoY) | -46.48% | -2.29% | 237.79% | 659.61% | -89.23% | Upgrade
|
| Cost of Revenue | 531.45 | 430.61 | 434.61 | 180.74 | 62.51 | Upgrade
|
| Gross Profit | -223.29 | 145.17 | 154.68 | -6.29 | -39.54 | Upgrade
|
| Selling, General & Admin | 50.55 | 59.35 | 34.2 | 40.33 | 37.09 | Upgrade
|
| Research & Development | 1.98 | 0.73 | - | - | - | Upgrade
|
| Other Operating Expenses | 2.96 | 6.3 | 4.12 | 3.14 | 2.42 | Upgrade
|
| Operating Expenses | -23.88 | 80.8 | 100.73 | 74.89 | 49.72 | Upgrade
|
| Operating Income | -199.41 | 64.37 | 53.94 | -81.18 | -89.27 | Upgrade
|
| Interest Expense | -26.84 | -22.02 | -15.87 | -10.29 | -4.42 | Upgrade
|
| Interest & Investment Income | 0.32 | 1.91 | 0.84 | 0.1 | 0.1 | Upgrade
|
| Currency Exchange Gain (Loss) | 0.94 | 0.96 | 3.16 | -0.8 | -2.41 | Upgrade
|
| Other Non Operating Income (Expenses) | 0.55 | 1.34 | -11.03 | -7.87 | -168.62 | Upgrade
|
| EBT Excluding Unusual Items | -224.44 | 46.56 | 31.04 | -100.05 | -264.62 | Upgrade
|
| Gain (Loss) on Sale of Investments | - | - | -0 | - | - | Upgrade
|
| Gain (Loss) on Sale of Assets | 0.74 | 40.57 | 0.22 | 0.23 | 0.02 | Upgrade
|
| Asset Writedown | - | - | -1.66 | -2.51 | -0.6 | Upgrade
|
| Legal Settlements | -0.2 | -0.58 | -0.03 | - | - | Upgrade
|
| Other Unusual Items | -8.74 | 22.82 | 1.8 | -4.54 | -0.03 | Upgrade
|
| Pretax Income | -232.64 | 109.37 | 31.38 | -106.87 | -265.22 | Upgrade
|
| Income Tax Expense | 0.26 | 0.22 | 5.29 | 0 | 1.5 | Upgrade
|
| Earnings From Continuing Operations | -232.9 | 109.15 | 26.08 | -106.87 | -266.72 | Upgrade
|
| Minority Interest in Earnings | 2.12 | -0.91 | 0 | 0.06 | 0.83 | Upgrade
|
| Net Income | -230.78 | 108.24 | 26.09 | -106.81 | -265.89 | Upgrade
|
| Net Income to Common | -230.78 | 108.24 | 26.09 | -106.81 | -265.89 | Upgrade
|
| Net Income Growth | - | 314.94% | - | - | - | Upgrade
|
| Shares Outstanding (Basic) | 771 | 771 | 870 | 763 | 782 | Upgrade
|
| Shares Outstanding (Diluted) | 771 | 771 | 870 | 763 | 782 | Upgrade
|
| Shares Change (YoY) | -0.02% | -11.27% | 13.96% | -2.44% | 57.17% | Upgrade
|
| EPS (Basic) | -0.30 | 0.14 | 0.03 | -0.14 | -0.34 | Upgrade
|
| EPS (Diluted) | -0.30 | 0.14 | 0.03 | -0.14 | -0.34 | Upgrade
|
| EPS Growth | - | 367.67% | - | - | - | Upgrade
|
| Free Cash Flow | -133.24 | -397.17 | 183.66 | -200.69 | -13.76 | Upgrade
|
| Free Cash Flow Per Share | -0.17 | -0.52 | 0.21 | -0.26 | -0.02 | Upgrade
|
| Gross Margin | -72.46% | 25.21% | 26.25% | -3.60% | -172.19% | Upgrade
|
| Operating Margin | -64.71% | 11.18% | 9.15% | -46.53% | -388.68% | Upgrade
|
| Profit Margin | -74.89% | 18.80% | 4.43% | -61.23% | -1157.76% | Upgrade
|
| Free Cash Flow Margin | -43.24% | -68.98% | 31.17% | -115.04% | -59.93% | Upgrade
|
| EBITDA | -162.95 | 105.27 | 98.72 | -35.54 | -42.31 | Upgrade
|
| EBITDA Margin | -52.88% | 18.28% | 16.75% | -20.37% | -184.21% | Upgrade
|
| D&A For EBITDA | 36.47 | 40.9 | 44.78 | 45.64 | 46.96 | Upgrade
|
| EBIT | -199.41 | 64.37 | 53.94 | -81.18 | -89.27 | Upgrade
|
| EBIT Margin | -64.71% | 11.18% | 9.15% | -46.53% | - | Upgrade
|
| Effective Tax Rate | - | 0.20% | 16.86% | - | - | Upgrade
|
| Revenue as Reported | 308.15 | 575.78 | 589.29 | 174.45 | 22.97 | Upgrade
|
| Advertising Expenses | 0.66 | 0.63 | 0.05 | - | - | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.